60 day FRN

Federal Register / Vol. 85, No. 14 / Wednesday, January 22, 2020 / Notices
D Healthcare utilization (use and
length of hospice care,
hospitalizations, advance directive
documentation) and costs and
resource use (use of outpatient
clinician services, including
palliative care)
Æ Adverse effects
D Medication side effects
D Dropouts
• Timing
Æ Any timing
• Settings
Æ Ambulatory primary and specialty
care, including geriatrics,
nephrology, pulmonology,
cardiology, and neurology
Æ U.S.-based studies, as systems of
care differ in other countries
Dated: January 15, 2020.
Virginia L. Mackay-Smith,
Associate Director, Office of the Director,
AHRQ.
[FR Doc. 2020–00903 Filed 1–21–20; 8:45 am]
BILLING CODE 4160–90–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[0Day–20–0006; Docket No. CDC–2019–
0118]

Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:

The Centers for Disease
Control and Prevention (CDC), as part of
its continuing effort to reduce public
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies the opportunity to comment on
a proposed and/or continuing
information collection, as required by
the Paperwork Reduction Act of 1995.
This notice invites comment on
Statements in Support of Application of
Waiver of Inadmissibility (0920–0006).
CDC uses the information collected in
0920–0006 to review Class A medical
waiver applications for prospective

khammond on DSKJM1Z7X2PROD with NOTICES

SUMMARY:

VerDate Sep<11>2014

16:42 Jan 21, 2020

Jkt 250001

immigrants to the United States. CDC
assists DHS/USCIS in determining
whether or not a prospective immigrant
with a Class A mental health
designation may be admitted into the
United States.
DATES: CDC must receive written
comments on or before March 23, 2020.
ADDRESSES: You may submit comments,
identified by Docket No. CDC–2019–
0118 by any of the following methods:
• Federal eRulemaking Portal:
Regulations.gov. Follow the instructions
for submitting comments.
• Mail: Jeffrey M. Zirger, Information
Collection Review Office, Centers for
Disease Control and Prevention, 1600
Clifton Road NE, MS–D74, Atlanta,
Georgia 30329.
Instructions: All submissions received
must include the agency name and
Docket Number. CDC will post, without
change, all relevant comments to
Regulations.gov.
Please note: Submit all comments
through the Federal eRulemaking portal
(regulations.gov) or by U.S. mail to the
address listed above.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the information collection plan and
instruments, contact Jeffrey M. Zirger, of
the Information Collection Review
Office, Centers for Disease Control and
Prevention, 1600 Clifton Road NE, MS–
D74, Atlanta, Georgia 30329; phone:
404–639–7570; Email: [email protected].
SUPPLEMENTARY INFORMATION: Under the
Paperwork Reduction Act of 1995 (PRA)
(44 U.S.C. 3501–3520), Federal agencies
must obtain approval from the Office of
Management and Budget (OMB) for each
collection of information they conduct
or sponsor. In addition, the PRA also
requires Federal agencies to provide a
60-day notice in the Federal Register
concerning each proposed collection of
information, including each new
proposed collection, each proposed
extension of existing collection of
information, and each reinstatement of
previously approved information
collection before submitting the
collection to the OMB for approval. To
comply with this requirement, we are
publishing this notice of a proposed
data collection as described below.
The OMB is particularly interested in
comments that will help:

PO 00000

Frm 00090

Fmt 4703

Sfmt 4703

3693

1. Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
2. Evaluate the accuracy of the
agency’s estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
3. Enhance the quality, utility, and
clarity of the information to be
collected; and
4. Minimize the burden of the
collection of information on those who
are to respond, including through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submissions
of responses.
5. Assess information collection costs.
Proposed Project
Statements in Support of Application
of Waiver of Inadmissibility (OMB
Control No. 0920–0006 Exp. 6/30/
2020)—Revision—National Center for
Emerging and Zoonotic Infectious
Diseases (NCEZID), Centers for Disease
Control and Prevention (CDC).
Background and Brief Description
Section 212(a)(1) of the Immigration
and Nationality Act states that aliens
with specific health related conditions
are ineligible for admission into the
United States. The Attorney General
may waive application of this
inadmissibility on health-related
grounds if an application for waiver is
filed and approved by the consular
office considering the application for
visa. CDC uses this application
primarily to collect information to
establish and maintain records of waiver
applicants in order to notify the U.S.
Citizenship and Immigration Services
when terms, conditions and controls
imposed by waiver are not met.
The purpose of this Revision is to
remove information collections for form
4.422–1a, because CDC does not receive
information about the evaluation report
of an applicant who received a waiver.
This results in a reduction of 67 burden
hours. CDC requests approval for 33
annual burden hours.

E:\FR\FM\22JAN1.SGM

22JAN1

3694

Federal Register / Vol. 85, No. 14 / Wednesday, January 22, 2020 / Notices
ESTIMATED ANNUALIZED BURDEN HOURS
Type of respondent

Average
burden
per response
(in hours)

Total
burden hours

Physician ..............................................................................

CDC 4.422–1

200

1

10/60

33

Total ..............................................................................

........................

........................

........................

........................

33

Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2020–01051 Filed 1–21–20; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
[OMB No. 0970–0492]

Submission for OMB Review;
Community Services Block Grant
Annual Report
Office of Community Services;
Administration for Children and
Families; HHS.
ACTION: Request for public comment.
The Administration of
Children and Families (ACF), Office of
Community Services (OCS) is requesting
a three-year extension with minor

SUMMARY:

changes of the Community Services
Block Grant (CSBG) Annual Report
(OMB No.: 0970–0492, expiration 1/31/
2020). This request will support the
currently utilized CSBG Annual Report,
comprised of Modules 1–4, and
incorporates performance management.
DATES: Comments due within 30 days of
publication. OMB is required to make a
decision concerning the collection of
information between 30 and 60 days
after publication of this document in the
Federal Register. Therefore, a comment
is best assured of having its full effect
if OMB receives it within 30 days of
publication.
Written comments and
recommendations for the proposed
information collection should be sent
directly to the following: Office of
Management and Budget, Paperwork
Reduction Project, Email: OIRA_
[email protected], Attn:
Desk Officer for the Administration for
Children and Families.
Copies of the proposed collection may
be obtained by emailing infocollection@

ADDRESSES:

AGENCY:

Annual
number of
respondents

Instrument

CSBG Annual Report (States) .........................................................................
CSBG Annual Report (Eligible Entities) ..........................................................

DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Authority: 112 Stat. 2729; 42 U.S.C.
9902(2).

Food and Drug Administration
[Docket Nos. FDA–2018–E–3053 and FDA–
2018–E–4226]

[FR Doc. 2020–00928 Filed 1–21–20; 8:45 am]
BILLING CODE 4184–27–P

Determination of Regulatory Review
Period for Purposes of Patent
Extension; MAVYRET
AGENCY:

Food and Drug Administration,

HHS.
ACTION:

Notice.

The Food and Drug
Administration (FDA or the Agency) has
determined the regulatory review period
for MAVYRET and is publishing this
notice of that determination as required
by law. FDA has made the

SUMMARY:

VerDate Sep<11>2014

16:42 Jan 21, 2020

Jkt 250001

PO 00000

Frm 00091

Fmt 4703

Sfmt 4703

acf.hhs.gov. Alternatively, copies can
also be obtained by writing to the
Administration for Children and
Families, Office of Planning, Research,
and Evaluation (OPRE), 330 C Street
SW, Washington, DC 20201, Attn: OPRE
Reports Clearance Officer. All requests,
emailed or written, should be identified
by the title of the information collection.
SUPPLEMENTARY INFORMATION:
Description: Module 1 includes minor
edits to align with the updated, and
OMB approved, CSBG State Plan.
Module 2, Module 3, and Module 4
include only technical and grammatical
updates for ease and clarity of current
reporting. Copies of the proposed
collection of information can be
obtained by visiting: http://
www.acf.hhs.gov/programs/ocs/
programs/csbg.
Respondents: State governments,
including the District of Columbia and
the Commonwealth of Puerto Rico, and
U.S. territories and CSBG eligible
entities (Community Action Agencies).
Annual Burden Estimates:
Annual
number of
responses per
respondent

52
1,009

Estimated Total Annual Burden
Hours: 713,569.

Mary B. Jones,
ACF/OPRE Certifying Officer.

khammond on DSKJM1Z7X2PROD with NOTICES

Number of
responses per
respondent

Number of
respondents

Form

1
1

Average
burden hours
per response
198
697

Annual burden
hours
10,296
703,273

determination because of the
submission of applications to the
Director of the U.S. Patent and
Trademark Office (USPTO), Department
of Commerce, for the extension of
patents which claims that human drug
product.
Anyone with knowledge that any
of the dates as published (see
SUPPLEMENTARY INFORMATION) are
incorrect may submit either electronic
or written comments and ask for a
redetermination by March 23, 2020.
Furthermore, any interested person may
petition FDA for a determination
regarding whether the applicant for
extension acted with due diligence
during the regulatory review period by
July 20, 2020. See ‘‘Petitions’’ in the
DATES:

E:\FR\FM\22JAN1.SGM

22JAN1